Search ABOUT PROGRAMS PLATFORM NEWS PUBLICATIONS INVESTORS CAREERS CONTACT BELIEVE ACHIEVE DIRECTORS STELIOS PAPADOPOULOS, PH.D., chairman Co-founder of several biotechnology companies and former Vice Chairman of Cowen & Company DAVID BALTIMORE, PH.D. Professor of Biology at the California Institute of Technology and the recipient of the 1975 Nobel Prize in Physiology or Medicine KATHRYN J. COLLIER Vice President for Audit Services for Sempra LNG JAY HAGAN President and Chief Executive Officer ALICE S. HUANG, PH.D. Senior Faculty Associate of Biology and Biological Engineering, California Institute of Technology JAKE R. NUNN Former Partner at New Enterprise Associates (NEA) WILLIAM H. RASTETTER, PH.D. Former Chief Executive Officer of IDEC Pharmaceuticals HUGH ROSEN, M.D., PH.D. Chairman and President of ActivX Biosciences, Inc. SIMOS SIMEONIDIS, PH.D. Partner at Sarissa Capital PASCALE WITZ Former Executive Vice President, Diabetes and Cardiovascular for Sanofi, S.A. © 2021 Regulus Therapeutics Inc. - All Rights Reserved Home | Legal | Contact

Search ABOUT PROGRAMS PLATFORM NEWS PUBLICATIONS INVESTORS CAREERS CONTACT BELIEVE ACHIEVE ABOUT microRNAS microRNAs are small naturally occurring non-coding RNAs that are 20 to 25 nucleotides in length. microRNAs regulate expression of target genes through sequence-specific hybridization to the 3′ untranslated region (UTR) of messenger RNAs and either block translation or direct degradation of their target messenger RNAs. This novel class of small non-coding RNAs was first discovered in the model organism C. elegans in 1993 and since then microRNAs have been identified in almost every species, including humans. They are highly conserved and research has shown that microRNAs function as important regulators of gene expression and play a role in multiple cellular processes. Mechanism of Action microRNAs play an integral role in numerous biological processes, including the immune response, cell-cycle control, metabolism, viral replication, stem cell differentiation and human development. Most microRNAs are conserved across multiple species, indicating the evolutionary importance of these molecules as modulators of critical biological pathways. Indeed, microRNA expression or function is significantly altered in numerous diseases including cancer and fibrosis, as well as CNS, metabolic and inflammatory disorders. Targeting pathways of human disease with microRNA-based drugs represents a novel and potentially powerful therapeutic approach. There are about 2,600 predicted mature human microRNAs, 600 of which are considered to be well validated and provide a large space of novel target opportunities. © 2021 Regulus Therapeutics Inc. - All Rights Reserved Home | Legal | Contact